A major independent panel from the Food and Drug Administration could approve booster shots for Moderna’s and Johnson & Johnson COVID-19 vaccines within the next two-days.
Thursday’s meeting of the FDA’s Advisory Committee on Vaccines and Related Biologics will discuss the risks and benefits of recommending booster shots to Moderna’s COVID-19 vaccination. The meeting will end with a non-binding vote to issue a formal recommendation.
The committee will again meet on Friday to discuss Johnson & Johnson booster shots.
According to ABC newsIf the panel votes in favor of booster shots for both types of vaccines, the matter will then be sent to the FDA.
If the FDA makes a formal recommendation, it will be sent to the Centers for Disease Control and Prevention advisory committee on immunization practice. This committee has already scheduled meetings for approval of Moderna boosters and Johnson & Johnson boosters October 20 and 21. Discuss. Final approval must be given by Dr. Rochelle Wilensky, Director of the CDC.
ABC News believes that booster shots may be approved for emergency use as early as Oct. 22.
The New York TimesAccording to reports, the VRBPAC is more likely than other vaccine boosters to recommend Johnson & Johnson because of its slightly lower efficacy. Moderna vaccine recipients are also less likely to develop severe COVID-19 symptoms if they have had their last dose of vaccines.
On Friday, the VRBPAC will weigh in on a report by the National Institutes for Health that shows: mixing and matching different types of vaccines and booster dosesStill, there was a strong immune response.
Researchers wrote that “these data suggest that if vaccines are approved or authorized to be used as boosters, an immune reaction will be generated regardless the primary COVID-19 vaccine regimen.”
The research has not been peer-reviewed.
FDA and CDC both have already approved booster shotsPfizer COVID-19 vaccine is recommended for those 65 and over, as well as people with underlying conditions or people who hold important jobs. These Americans should get a booster from Pfizer six months after receiving their second dose, according to the FDA.